A Phase I Dose Escalation Study of Repeated Administration of "CYT107" (glyco-r-hIL-7) Add On Treatment in Genotype 1 HCV Infected Patients Resistant to 12 Weeks Peg-Interferon-Alpha / Ribavirin.

Trial Profile

A Phase I Dose Escalation Study of Repeated Administration of "CYT107" (glyco-r-hIL-7) Add On Treatment in Genotype 1 HCV Infected Patients Resistant to 12 Weeks Peg-Interferon-Alpha / Ribavirin.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2012

At a glance

  • Drugs Interleukin-7; Peginterferon alfa; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Acronyms ECLIPSE-1
  • Sponsors Cytheris
  • Most Recent Events

    • 07 Dec 2009 Additional trial identifier NCT01025596 identified and inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
    • 06 Dec 2009 Additional lead trial centresand investigators identified as reported by ClinicalTrials.gov.
    • 06 Dec 2009 New source identified and integrated (ClinicalTrials.gov record no. NCT01025596).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top